Literature DB >> 25813985

The effect of disease risk probability and disease type on interest in clinic-based versus direct-to-consumer genetic testing services.

Kerry Sherman1,2, Laura-Kate Shaw3, Katrina Champion4, Fernanda Caldeira5, Margaret McCaskill3.   

Abstract

The effect of disease-specific cognitions on interest in clinic-based and direct-to-consumer (DTC) genetic testing was assessed. Participants (N = 309) responded to an online hypothetical scenario and received genetic testing-related messages that varied by risk probability (25, 50, 75 %) and disease type (Alzheimer's disease vs. Type 2 Diabetes). Post-manipulation interest increased for both testing types, but was greater for clinic-based testing. Interest was greater for Type 2 Diabetes than for Alzheimer's disease, the latter perceived as more severe and likely, and less treatable and preventable. For DTC testing only, participants allocated to the high risk condition (75 %) had greater testing interest than those in the low (25 %) category. DTC testing is perceived as a viable, but less preferred, option compared with clinic-based testing. Particularly when considering DTC genetic testing, there is a need to emphasize subjective disease-related perceptions, including risk probability.

Entities:  

Keywords:  Direct-to-consumer; Genetic testing; Perceived manageability; Perceived severity; Risk probability

Mesh:

Year:  2015        PMID: 25813985     DOI: 10.1007/s10865-015-9630-9

Source DB:  PubMed          Journal:  J Behav Med        ISSN: 0160-7715


  30 in total

1.  Lay Attitudes toward Genetic Testing for Susceptibility to Inherited Diseases.

Authors:  J S Shaw; K L Bassi
Journal:  J Health Psychol       Date:  2001-07

2.  Impact of genetic risk information and type of disease on perceived risk, anticipated affect, and expected consequences of genetic tests.

Authors:  Linda D Cameron; Kerry A Sherman; Theresa M Marteau; Paul M Brown
Journal:  Health Psychol       Date:  2009-05       Impact factor: 4.267

3.  Direct-to-consumer genetic testing: good, bad or benign?

Authors:  T Caulfield; N M Ries; P N Ray; C Shuman; B Wilson
Journal:  Clin Genet       Date:  2009-11-21       Impact factor: 4.438

4.  Communication strategies for enhancing understanding of the behavioral implications of genetic and biomarker tests for disease risk: the role of coherence.

Authors:  Linda D Cameron; Theresa M Marteau; Paul M Brown; William M P Klein; Kerry A Sherman
Journal:  J Behav Med       Date:  2011-06-23

Review 5.  Direct-to-consumer genomic testing: systematic review of the literature on user perspectives.

Authors:  Lesley Goldsmith; Leigh Jackson; Anita O'Connor; Heather Skirton
Journal:  Eur J Hum Genet       Date:  2012-02-15       Impact factor: 4.246

6.  Stigma by association and Alzheimer's disease.

Authors:  P Werner; J Heinik
Journal:  Aging Ment Health       Date:  2008-01       Impact factor: 3.658

7.  Public interest in predictive genetic testing, including direct-to-consumer testing, for susceptibility to major depression: preliminary findings.

Authors:  Alex Wilde; Bettina Meiser; Philip B Mitchell; Peter R Schofield
Journal:  Eur J Hum Genet       Date:  2010-01       Impact factor: 4.246

8.  Genetic testing for late-onset diseases: effect of disease controllability, test predictivity, and gender on the decision to take the test.

Authors:  Sivia Barnoy
Journal:  Genet Test       Date:  2007

9.  Direct-to-consumer genetic testing: a comprehensive view.

Authors:  Pascal Su
Journal:  Yale J Biol Med       Date:  2013-09-20

10.  Characteristics of users of online personalized genomic risk assessments: implications for physician-patient interactions.

Authors:  Colleen M McBride; Sharon Hensley Alford; Robert J Reid; Eric B Larson; Andreas D Baxevanis; Lawrence C Brody
Journal:  Genet Med       Date:  2009-08       Impact factor: 8.822

View more
  4 in total

1.  Current directions in behavioral medicine research on genetic testing for disease susceptibility: introduction to the special section.

Authors:  Kerry A Sherman; Linda D Cameron
Journal:  J Behav Med       Date:  2015-10

2.  Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature.

Authors:  Victoria S Marshe; Ilona Gorbovskaya; Sarah Kanji; Maxine Kish; Daniel J Müller
Journal:  J Neural Transm (Vienna)       Date:  2018-10-31       Impact factor: 3.575

3.  'I Don't Like Uncertainty, I Like to Know': How and why uveal melanoma patients consent to life expectancy prognostication.

Authors:  Stephen L Brown; Peter L Fisher; Andrew Morgan; Cari Davies; Yasmin Olabi; Laura Hope-Stone; Heinrich Heimann; Rumana Hussain; Mary Gemma Cherry
Journal:  Health Expect       Date:  2022-04-26       Impact factor: 3.318

4.  Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment.

Authors:  Kurt D Christensen; Jason Karlawish; J Scott Roberts; Wendy R Uhlmann; Kristin Harkins; Elisabeth M Wood; Thomas O Obisesan; Lan Q Le; L Adrienne Cupples; Emilie S Zoltick; Megan S Johnson; Margaret K Bradbury; Leo B Waterston; Clara A Chen; Sara Feldman; Denise L Perry; Robert C Green
Journal:  Alzheimers Dement (N Y)       Date:  2020-03-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.